Herein, we describe a carrier-free co-assembled system of dual therapeutic agents that combines immunotherapy and sonodynamic therapy to enhance antitumor therapy (Scheme 1). Firstly, we obtained an ion complementary peptide compound EH (sequence: EYNFDFKFNYH) that can target PD-L1 through the peptide library construction and screening strategy previously developed in our group .